Agenus Inc. has announced the publication of clinical results from the ovarian cancer cohort of its Phase 1b C-800-01 trial evaluating botensilimab plus balstilimab (BOT+BAL) in The Journal for ImmunoTherapy of Cancer (JITC). The study included women with treatment-refractory ovarian cancer, a population with limited remaining treatment options. In this heavily pretreated group, BOT+BAL demonstrated a 23% overall response rate and a 31% clinical benefit rate, with a median duration of response of 9.7 months. Median overall survival reached 14.8 months, with an estimated 75% of patients alive at 12 months. These results have already been published and build on data from the broader C-800-01 dataset previously presented at ESMO 2025. Agenus is continuing global clinical development of BOT+BAL across multiple tumor types and is providing access to the combination through early access programs in select countries.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agenus Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251223989276) on December 23, 2025, and is solely responsible for the information contained therein.